Welcome to In the Spotlight, where each month we shine a light on something exciting, timely, or simply fascinating from the world of science.
This month, we’re focusing on infectious diseases, a topic that affects lives and communities around the world. Here, you’ll find the latest research news, insights, and discoveries shaping how infectious diseases are being studied, prevented, and treated globally.
Latest News Releases
Updates every hour. Last Updated: 14-Dec-2025 01:11 ET (14-Dec-2025 06:11 GMT/UTC)
Uncovering the hidden emerging pathogen behind Aspergillosis cases in Japan
Chiba UniversityPeer-Reviewed Publication
Aspergillus, a common mold-forming fungus, can cause severe respiratory disease in patients with reduced immunity. Through screening 23 A. spinulosporus strains, researchers have identified, for the first time, seven clinical A. latus strains in patient samples. Their discovery of A. latus strains in samples obtained between 2012 and 2023 revealed a high misidentification rate of 30.4%. Continued surveillance and improved diagnostic tools can aid in the clinical management of Aspergillus infections.
- Journal
- Medical Mycology
- Funder
- JSPS KAKENHI, Institute for Fermentation
Korea University study proposes first toxicity-based exposure limits proposed for indoor airborne fungi
Korea University College of MedicinePeer-Reviewed Publication
Airborne microorganisms, including fungi and bacteria, are major contributors to indoor air pollution, with growing links to respiratory diseases. In a recent study, scientists from Korea explored the health effects of common airborne microbes by testing their toxicity in mice and calculating human-equivalent exposure limits. The results revealed that some fungi can cause lung inflammation and injury even at concentrations below current guideline levels, highlighting the need for species-specific indoor air quality standards.
- Journal
- Journal of Hazardous Materials
Estimated burden of influenza and direct and indirect benefits of influenza vaccination
JAMA NetworkPeer-Reviewed Publication
- Journal
- JAMA Network Open
Avian flu has major economic costs for dairy industry
Cornell UniversityPeer-Reviewed Publication
- Journal
- Nature Communications
Funding for lifesaving global health programs forecasted to reach 15-year low, threatening to reverse decades of progress
Institute for Health Metrics and EvaluationReports and Proceedings
The Lundquist Institute wins multi-year NIH grant exceeding $11 million to transform diagnosis and treatment of deadly mucormycosis
The Lundquist InstituteGrant and Award Announcement
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA (TLI) announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a new grant (P01AI186818) to Dr. Ashraf S. Ibrahim, PhD, a TLI Investigator, a Professor of Medicine at David Geffen School of Medicine at UCLA, and a leading authority on mucormycosis pathogenesis. The grant provides $2.2 million in first-year funding and $11,269,858 million in total projected support over the next five years to launch MUCOR-ADVANCE, an ambitious effort to revolutionize risk stratification, early diagnosis, and treatment of mucormycosis, one of the world’s most lethal fungal infections.
- Funder
- NIH/National Institute of Allergy and Infectious Diseases